509 filings
Page 15 of 26
6-K
0vkjcpi6
27 Oct 22
Current report (foreign)
4:17pm
6-K
wdrdltx
27 Oct 22
GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
7:17am
6-K
l0ppi
21 Oct 22
Current report (foreign)
10:31am
6-K
ulttzf2omm x2k
21 Oct 22
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
7:39am
6-K
3dukx6hqinmr s9x
12 Oct 22
Current report (foreign)
10:22am
6-K
slz55autxwvlzr2kl h2
11 Oct 22
Current report (foreign)
10:25am
6-K
zshpto0ovylu4 u2w2
11 Oct 22
Current report (foreign)
10:08am
6-K
axhvwymzos6hwdz3jr8
6 Oct 22
Current report (foreign)
10:23am
6-K
1mvlcen9l 2h
28 Sep 22
Current report (foreign)
5:04pm
6-K
1um 20ndfzgrrs0
22 Sep 22
Current report (foreign)
10:52am
6-K
bggy27s
19 Sep 22
Current report (foreign)
10:51am
6-K
el1 e3mokpizi7fuv2d
31 Aug 22
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
4:08pm
6-K
sdfsuh8 7ii1ij
4 Aug 22
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
9:06am
6-K
nt0eb4em3mbtx18xt3d
3 Aug 22
Half-Year Report JANUARY – JUNE 2022
4:36pm
6-K
7dhjz lfjy7v3w
29 Jul 22
Conference Call Alert
6:13am
6-K
94jc9s6 c5p215
26 Jul 22
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
9:17am
6-K
pyfyn892xic 1m2oiaz
23 Jun 22
First Quarter Interim Statement JANUARY – MARCH
6:30am
6-K
66uhaerlrymjzsz 728
14 Jun 22
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
4:08pm
6-K
1dcch7u29yc
13 Jun 22
Current report (foreign)
4:07pm
6-K
9qnavt93
10 Jun 22
Current report (foreign)
7:16am